Comparison of Eligibility Criteria and Baseline Characteristics Between the Patient Populations of evoke and evoke+, Clarity AD and TRAILBLAZER-ALZ-2 (P12-3.018)
To compare the evoke and evoke+ trial populations with other phase 3 programs for disease-modifying therapy (DMT) in early Alzheimer’s disease (AD).
Authors
- Lars Bardtrum
- Peter Johannsen (ORCID: https://orcid.org/0000-0002-0528-1070)
- Philip Scheltens (ORCID: https://orcid.org/0000-0002-1046-6408)
- Wiesje M. van der Flier (ORCID: https://orcid.org/0000-0001-8766-6224)
- Charlotte T. Hansen
- Howard Feldman (ORCID: https://orcid.org/0000-0002-9258-4538)
- Oskar Hansson (ORCID: https://orcid.org/0000-0001-8467-7286)
- Paul Mystkowski
- Rose Jeppesen (ORCID: https://orcid.org/0000-0002-9984-2202)
- Jeffrey L. Cummings (ORCID: https://orcid.org/0000-0001-8944-4158)
- Teresa León (ORCID: https://orcid.org/0000-0001-5171-4159)
- Mary Sano
Institutions
- University of Nevada, Reno (US)
- Lund University (SE)
- Novo Nordisk (Denmark) (DK)
- University of California San Diego (US)
- Alzheimer’s Disease Neuroimaging Initiative (US)
- Amsterdam Neuroscience (NL)
- James J. Peters VA Medical Center (US)
- Novo Nordisk (United Kingdom) (GB)
- Skåne University Hospital (SE)
- Amsterdam University Medical Centers (NL)
- The Memory Clinic (US)
- Vrije Universiteit Amsterdam (NL)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000211264
- Primary Topic
- Traditional Chinese Medicine Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00